Drug Description in Trials / DrugBank / KEGG DRUG


Search results


No. 薬物名(臨床試験情報から抽出) DrugBank KEGG DRUG KEGG GENES KEGG PATHWAY 指定難病告示番号
120 mg/ml Treprostinil1件: Treprostinil1件: D06213 (Name: Treprostinil)1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
2Abatacept Active Treatment1件: Abatacept1件: D03203 2件: CD80,
CD86 💬
13件: Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules, Graft-versus-host disease, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Rheumatoid arthritis, Systemic lupus erythematosus, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis, Virion - Adenovirus 💬1件: 50
3Abatacept Delayed-Onset Treatment1件: Abatacept1件: D03203 2件: CD80,
CD86 💬
13件: Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules, Graft-versus-host disease, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Rheumatoid arthritis, Systemic lupus erythematosus, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis, Virion - Adenovirus 💬1件: 50
4Active Investigational Treatment ENT-01----1件: 6
5Active Treatment Group 7% Hypertonic Saline----1件: 299
6Aesculus Hippocastanum / Horse Chestnut
(Synonym: Conker tree)
1件: Horse chestnut1件: D12028 (Name: Conker tree)--1件: 210
7All patients in the study will be treated with ocrelizumab1件: Ocrelizumab1件: D05218 1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 13
8Baclofen (baclofen Tab. 10mg) treatment1件: Baclofen1件: D00241 2件: GABBR1,
GABBR2 💬
7件: Estrogen signaling pathway, GABAergic synapse, GnRH secretion, Morphine addiction, Neuroactive ligand-receptor interaction, Taste transduction, cAMP signaling pathway 💬1件: 70
9Baricitinib treatment1件: Baricitinib1件: D10308 2件: JAK1,
JAK2 💬
35件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬1件: 46
10Baseline Treatment----1件: 13
11BDMARD treatment----1件: 271
12Bendamustine
(Synonym: Treanda (TN))
1件: Bendamustine (Synonym: Treanda)1件: D07501 (Name: Treanda (TN))--2件: 28, 61
13BENDAMUSTINE HYDROCHLORIDE
(Synonym: Treanda (TN))
1件: Bendamustine (Synonym: Treanda)1件: D07501 (Name: Treanda (TN))--1件: 61
14Bendamustine, Rituximab
(Synonym: Treanda (TN))
2件: Bendamustine (Synonym: Treanda),
Rituximab
2件: D02994 ,
D07501 (Name: Treanda (TN))
1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 61
15Best Medical Treatment----1件: 6
16Best médical treatment----1件: 6
17Bisphosphonate treatment----2件: 113, 299
18Botulism Toxin Treatment----1件: 161
19Break in L-carnitine treatment1件: Levocarnitine1件: D02176 --1件: 316
20C-Trelin OD Tab(5mg Taltirelin Hydrate)----1件: 18
21Carbidopa/levodopa, as prescribed by treating physician2件: Carbidopa,
Levodopa
2件: D00059 ,
D00558
6件: DDC,
DRD1,
DRD2,
DRD3,
DRD4,
DRD5 💬
16件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬1件: 6
22CF patients with a G551D mutation and treated with Ivacaftor1件: Ivacaftor1件: D09916 1件: CFTR 💬8件: ABC transporters, AMPK signaling pathway, Bile secretion, Gastric acid secretion, Pancreatic secretion, Tight junction, Vibrio cholerae infection, cAMP signaling pathway 💬1件: 299
23Chinese herbal medicine treatment----1件: 6
24Classic DMARDs treatment group----1件: 46
25Clobetasol Propionate cream treatment2件: Clobetasol,
Clobetasol propionate
2件: D01272 ,
D07715
1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 162
26Clopidogrel treatment1件: Clopidogrel3件: D07729 ,
D10823 ,
D10824
1件: P2RY12 💬1件: Platelet activation 💬1件: 51
27Combination Product: Active treatment with dual therapy----1件: 2
28Combination Product: Implantable System for Remodulin (treprostinil)1件: Treprostinil1件: D06213 (Name: Treprostinil)1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
29Combination Product: Treprostinil via implanted pump1件: Treprostinil1件: D06213 (Name: Treprostinil)1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
30Conventional treatment----1件: 97
31Conventional treatment (glucocoticoid, immunosupressive drugs and/or mesalazine)1件: Mesalazine1件: D00377 --2件: 96, 97
32Corticosteroid treatment (Methylprednisolone or prednisolone)2件: Methylprednisolone,
Prednisolone
2件: D00407 ,
D00472
1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 64
33Crysvita (burosumab-twza) Treatment1件: Burosumab1件: D10913 1件: FGF23 💬11件: Breast cancer, Calcium signaling pathway, Gastric cancer, MAPK signaling pathway, Melanoma, PI3K-Akt signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton 💬1件: 238
34Current lipid-lowering treatment----1件: 79
35Current treatment of AL-CM----1件: 28
36Cutaneous iontophoresis of treprostinil1件: Treprostinil1件: D06213 (Name: Treprostinil)1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 51
37Cytokine-treated Veto Cells----1件: 60
38Deferiprone treated1件: Deferiprone1件: D07416 --1件: 120
39Detoxifying agents for antineoplastic treatment----2件: 299, 337
40Dietanolamina de treprostinilo1件: Treprostinil1件: D06213 (Name: Treprostinil)1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
41Disease modifying treatment (DMT)----1件: 13
42Disease modifying treatments----1件: 3
43Dopamine agonist treatment1件: Dopamine1件: D07870 5件: DRD1,
DRD2,
DRD3,
DRD4,
DRD5 💬
11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬1件: 74
44Drug treatment----3件: 51, 74, 271
45ERA as specific PAH treatment----1件: 86
46Etanercept Treatment1件: Etanercept1件: D00742 2件: LTA,
TNF 💬
67件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬1件: 46
47Eutonic Treprostinil Solution1件: Treprostinil1件: D06213 (Name: Treprostinil)1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
48Experimental (Non Immunosuppressive Symptomatic Treatment (NIST) and Rituximab)1件: Rituximab1件: D02994 1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 222
49Exposure to one or more disease-modifying drug(s)(DMDs) used to treat MS----1件: 13
50Fibrate treatment----1件: 160
51Foliglurax 10 mg (treatment A)1件: Foliglurax---1件: 6
52Foliglurax 30 mg (treatment B)1件: Foliglurax---1件: 6
53Follow-up study of the treated cohort----1件: 193
54From August 2020 'no additional treatment'----1件: 51
55Gabapentin (neurontin® capsule 300mg) treatment1件: Gabapentin1件: D00332 5件: CACNA2D1,
CACNA2D2,
CACNA2D3,
CACNA2D4,
SLC6A1 💬
9件: Adrenergic signaling in cardiomyocytes, Arrhythmogenic right ventricular cardiomyopathy, Cardiac muscle contraction, Dilated cardiomyopathy, GABAergic synapse, Hypertrophic cardiomyopathy, MAPK signaling pathway, Oxytocin signaling pathway, Synaptic vesicle cycle 💬1件: 70
56GENOTROPIN (Somatropin) is a growth hormone treatment. It is an exact copy of the natural growth hormone that our bodies make. The main difference is that GENOTROPIN is man-made.1件: Somatotropin---1件: 193
57Glucocorticoid Treatment----1件: 41
58Golimumab treatment optimization.1件: Golimumab1件: D04358 1件: TNF 💬67件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬1件: 97
59Group 1 or Orencia treated group1件: Abatacept1件: D03203 2件: CD80,
CD86 💬
13件: Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules, Graft-versus-host disease, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Rheumatoid arthritis, Systemic lupus erythematosus, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis, Virion - Adenovirus 💬1件: 46
60GUSELKUMAB
(Synonym: Tremfya (TN))
1件: Guselkumab (Synonym: Tremfya)1件: D10438 (Name: Tremfya (TN))1件: IL23A 💬9件: C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬5件: 37, 41, 51, 96, 97
61Guselkumab 100 mg
(Synonym: Tremfya (TN))
1件: Guselkumab (Synonym: Tremfya)1件: D10438 (Name: Tremfya (TN))1件: IL23A 💬9件: C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬1件: 37
62Guselkumab Dose 1
(Synonym: Tremfya (TN))
1件: Guselkumab (Synonym: Tremfya)1件: D10438 (Name: Tremfya (TN))1件: IL23A 💬9件: C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬3件: 51, 96, 97
63Guselkumab Dose 2
(Synonym: Tremfya (TN))
1件: Guselkumab (Synonym: Tremfya)1件: D10438 (Name: Tremfya (TN))1件: IL23A 💬9件: C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬3件: 51, 96, 97
64Guselkumab Dose 3
(Synonym: Tremfya (TN))
1件: Guselkumab (Synonym: Tremfya)1件: D10438 (Name: Tremfya (TN))1件: IL23A 💬9件: C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬2件: 96, 97
65Guselkumab Dose 4
(Synonym: Tremfya (TN))
1件: Guselkumab (Synonym: Tremfya)1件: D10438 (Name: Tremfya (TN))1件: IL23A 💬9件: C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬1件: 96
66Guselkumab Dose 5
(Synonym: Tremfya (TN))
1件: Guselkumab (Synonym: Tremfya)1件: D10438 (Name: Tremfya (TN))1件: IL23A 💬9件: C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬1件: 96
67HAESCs treatment----1件: 6
68HCQ/CQ and CAB combined treatment----1件: 74
69Herbal treatment (SA100)----1件: 97
70Horse chestnut
(Synonym: Conker tree)
1件: Horse chestnut1件: D12028 (Name: Conker tree)--1件: 210
71Hyperpolarized 129 Xenon Gas Comparing Idiopathic Pulmonary Fibrosis (IPF) Treatment1件: Xenon2件: D01901 ,
D06339
--1件: 85
72Hyperpolarized 129 Xenon Gas Comparing Progressive Pulmonary Fibrosis Treatment1件: Xenon2件: D01901 ,
D06339
--1件: 85
73Immunosuppressive treatment----1件: 66
74Immunosuppressive treatment (eg, rituximab)1件: Rituximab1件: D02994 1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 64
75In double-blind phase: treatment with tofacitinib1件: Tofacitinib1件: D09970 4件: JAK1,
JAK2,
JAK3,
TYK2 💬
37件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬1件: 107
76In open-label phase: treatment with tofacitinib1件: Tofacitinib1件: D09970 4件: JAK1,
JAK2,
JAK3,
TYK2 💬
37件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬1件: 107
77Inhaled dry powder treprostinil (LIQ861)1件: Treprostinil1件: D06213 (Name: Treprostinil)1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
78Inhaled Treprostinil1件: Treprostinil1件: D06213 (Name: Treprostinil)1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬3件: 84, 85, 86
79Interferon beta treatment to add-on atorvastatin treatment2件: Atorvastatin,
Human interferon beta
1件: D07474 1件: HMGCR 💬4件: AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis 💬1件: 13
80Intravenous Treprostinil1件: Treprostinil1件: D06213 (Name: Treprostinil)1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
81Iontophoresis of treprostinil1件: Treprostinil1件: D06213 (Name: Treprostinil)1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 51
82IV treatment with IGSC, 10%----1件: 65
83L606 (Liposomal Treprostinil) Inhalation Solution 51ug1件: Treprostinil1件: D06213 (Name: Treprostinil)1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
84Lapaquistat acetate and current lipid-lowering treatment2件: Acetate,
Lapaquistat
---1件: 79
85Large dose of prednisolone plus intra-lesional of Triamcinolone Acetonide followed the systemic combination of mycophenolate mofetil (MMF), dapsone and low dose prednisolone in treatment of MMP5件: Dapsone,
Mycophenolate mofetil,
Mycophenolic acid,
Prednisolone,
Triamcinolone (Synonym: Treziopak)
5件: D00385 ,
D00472 ,
D00592 ,
D00752 ,
D05096
3件: IMPDH1,
IMPDH2,
NR3C1 💬
5件: Drug metabolism - other enzymes, Metabolic pathways, Neuroactive ligand-receptor interaction, Nucleotide metabolism, Purine metabolism 💬1件: 162
86LIQ861 Inhaled Treprostinil1件: Treprostinil1件: D06213 (Name: Treprostinil)1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
87Lumacaftor-Ivacaftor treatment2件: Ivacaftor,
Lumacaftor
2件: D09916 ,
D10134
1件: CFTR 💬8件: ABC transporters, AMPK signaling pathway, Bile secretion, Gastric acid secretion, Pancreatic secretion, Tight junction, Vibrio cholerae infection, cAMP signaling pathway 💬1件: 299
88Metformin treatment1件: Metformin1件: D04966 2件: PRKAA1,
PRKAA2 💬
20件: AMPK signaling pathway, Adipocytokine signaling pathway, Alcoholic liver disease, Apelin signaling pathway, Autophagy - animal, Circadian rhythm, Fluid shear stress and atherosclerosis, FoxO signaling pathway, Glucagon signaling pathway, Hypertrophic cardiomyopathy, Insulin resistance, Insulin signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Non-alcoholic fatty liver disease, Oxytocin signaling pathway, PI3K-Akt signaling pathway, Thermogenesis, Tight junction, mTOR signaling pathway 💬1件: 46
89Methotrexate treatment1件: Methotrexate (Synonym: Trexall)1件: D00142 2件: DHFR,
DHFR2 💬
5件: Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬2件: 41, 46
90MK0812 / Duration of Treatment: 12 Weeks----1件: 46
91Monthly autologous Treg cells infusions + 3 times per week Interleukin-2 injections1件: Human interleukin-2---1件: 2
92MSC treatment----1件: 49
93MSC treatment 01----1件: 96
94MSC treatment 02----1件: 96
95Natalizumab treatment1件: Natalizumab1件: D06886 1件: ITGA4 💬14件: Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection 💬1件: 13
96Nifurtimox-Eflronithine Combination Treatment (NECT)1件: Nifurtimox1件: D00833 --1件: 65
97Nusinersen Treatments1件: Nusinersen1件: D10881 1件: SMN2 💬-1件: 3
98Nutrition treat----1件: 96
99Observational study with patients treated with Tracleer, Ventavis, Veletri, Opsumit and/or Uptravi4件: Epoprostenol,
Iloprost,
Macitentan,
Selexipag
4件: D00106 ,
D02721 ,
D09994 ,
D10135
3件: EDNRA,
EDNRB,
PTGIR 💬
10件: Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Platelet activation, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 86
100OC oral solution treatment A----1件: 6
101OC oral solution treatment B----1件: 6
102OC oral solution treatment C----1件: 6
103OC oral solution treatment D----1件: 6
104Only 1 arm: treatment with MSC-AFP----1件: 96
105Optimized antiparkinsonian treatment----1件: 6
106Optimized Medical Treatment----1件: 6
107Optimized oral treatment----1件: 6
108Oral anticoagulant treatment----1件: 86
109Oral treprostinil1件: Treprostinil1件: D06213 (Name: Treprostinil)1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬2件: 51, 86
110Oral treprostinil (UT-15C) Sustained Release Tablets1件: Treprostinil1件: D06213 (Name: Treprostinil)1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
111Other Parkinson's Disease treatments----1件: 6
112Ova-Treg----1件: 96
113Ovastat 1000 (Treosulfan injection)1件: Treosulfan1件: D07253 (Name: Treosulfan)--1件: 65
114Ovastat 5000 (Treosulfan injection)1件: Treosulfan1件: D07253 (Name: Treosulfan)--1件: 65
115Parenteral Remodulin (treprostinil) injection1件: Treprostinil1件: D06213 (Name: Treprostinil)1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
116Parenteral Treprostinil1件: Treprostinil1件: D06213 (Name: Treprostinil)1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
117Patient treated with DMARD----1件: 46
118Pentoxifylline
(Synonym: Trental (TN))
1件: Pentoxifylline (Synonym: Trental Srt 400mg)1件: D00501 (Name: Trental (TN))--12件: 26, 56, 84, 86, 93, 96, 97, 113, 220, 222, 296, 298
119Pentoxifylline 400 MG
(Synonym: Trental (TN))
1件: Pentoxifylline (Synonym: Trental Srt 400mg)1件: D00501 (Name: Trental (TN))--1件: 97
120Perfusion of treatment Ocrelizumab1件: Ocrelizumab1件: D05218 1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 13
121Perfusion of treatment Rituximab1件: Rituximab1件: D02994 1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 13
122Pharmacologic approaches to glycemic treatment----1件: 298
123Pioglitazone and Tretinoin2件: Pioglitazone,
Tretinoin
2件: D00094 (Name: Tretinoin),
D08378
4件: PML,
PPARG,
RARA,
RARB 💬
21件: AMPK signaling pathway, Acute myeloid leukemia, Endocytosis, Estrogen signaling pathway, Gastric cancer, Herpes simplex virus 1 infection, Huntington disease, Influenza A, Lipid and atherosclerosis, Longevity regulating pathway, Non-alcoholic fatty liver disease, Non-small cell lung cancer, Osteoclast differentiation, PPAR signaling pathway, Pathways in cancer, Small cell lung cancer, Th17 cell differentiation, Thermogenesis, Thyroid cancer, Transcriptional misregulation in cancer, Ubiquitin mediated proteolysis 💬1件: 2
124Plasma from healthy young people treatment + Riluzole1件: Riluzole1件: D00775 14件: GRIA1,
GRIA2,
GRIA3,
GRIA4,
GRIK1,
GRIK2,
GRIK3,
GRIK4,
GRIK5,
GRIN1,
GRIN2A,
GRIN2B,
GRIN2C,
GRIN2D 💬
23件: Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term depression, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases, Prion disease, Rap1 signaling pathway, Ras signaling pathway, Retrograde endocannabinoid signaling, Spinocerebellar ataxia, Systemic lupus erythematosus, Transcriptional misregulation in cancer, cAMP signaling pathway 💬1件: 2
125Pooled Plasma (Human), Solvent/Detergent Treated----1件: 64
126PPI treatment----1件: 299
127Prednisone and ustekinumab treatment2件: Prednisone,
Ustekinumab
2件: D00473 ,
D09214
4件: IL12A,
IL12B,
IL23A,
NR3C1 💬
29件: African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, Inflammatory bowel disease, Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, Malaria, Measles, Neuroactive ligand-receptor interaction, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus 💬1件: 41
128Prednisone treatment1件: Prednisone1件: D00473 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 41
129Propranolol treatment1件: Propranolol1件: D08443 3件: ADRB1,
ADRB2,
ADRB3 💬
12件: Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy, Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Thermogenesis, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 227
130Rapid Dose Titration Group of Subcutaneous Treprostinil1件: Treprostinil1件: D06213 (Name: Treprostinil)1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
131Regular treatment----1件: 97
132Remodulin (treprostinil sodium)1件: Treprostinil1件: D06213 (Name: Treprostinil)1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
133Remodulin® (treprostinil) 1 mg/ml solution for infusion1件: Treprostinil1件: D06213 (Name: Treprostinil)1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
134Remodulin® (treprostinil) 10 mg/ml solution for infusion1件: Treprostinil1件: D06213 (Name: Treprostinil)1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
135Remodulin® (treprostinil) 2.5 mg/ml solution for infusion1件: Treprostinil1件: D06213 (Name: Treprostinil)1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
136Remodulin® (treprostinil) 5 mg/ml solution for infusion1件: Treprostinil1件: D06213 (Name: Treprostinil)1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
137Routine Treatment of CD----1件: 96
138Sc recombinant growth hormone + amitriptyline, fluoxetine and tramadol (treated group)4件: Amitriptyline,
Fluoxetine,
Somatotropin,
Tramadol
3件: D00326 ,
D07448 ,
D08623
3件: OPRM1,
SLC6A2,
SLC6A4 💬
5件: Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Serotonergic synapse, Synaptic vesicle cycle 💬1件: 78
139SC treatment with IGSC, 10% with rHuPH20 followed by IV/IGSC, 10% only (safety)----1件: 65
140SC treatment with IGSC, 10% with rHuPH20 followed by SC/IGSC, 10% only (safety)----1件: 65
141Simvastatin treatment for 28 days1件: Simvastatin1件: D00434 1件: HMGCR 💬4件: AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis 💬1件: 299
142Slow Dose Titration Group of Subcutaneous Treprostinil1件: Treprostinil1件: D06213 (Name: Treprostinil)1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
143SLS-005 Trehalose1件: Trehalose---1件: 2
144Somatropin - GH treated cohort1件: Somatotropin---1件: 193
145Standard of Care Treatment----3件: 53, 245, 246
146Standard Steroid Treatment----1件: 85
147Standard treatment with a conventional drug----1件: 13
148Standard-of-care treatment----1件: 49
149Standrd of Care treatment----1件: 64
150Study treatment PPI----1件: 166
151Subcutaneous Treprostinil1件: Treprostinil1件: D06213 (Name: Treprostinil)1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
152Symptomatic treatment (Converting Enzyme inhibitor, Angiotensin II, Anti-renin, Aldosterone antagonist diuretic, Beta blocker, Calcium inhibitor, statin)3件: Aldosterone,
Angiotensin II,
Calcium (Synonym: Restoration Treatment)
3件: D00150 ,
D02014 ,
D10528
3件: AGTR1,
AGTR2,
NR3C2 💬
17件: AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Aldosterone-regulated sodium reabsorption, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease - COVID-19, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬1件: 222
153Symptomatic Treatment, Steroids, Immunosuppressive Agents, Plasma Exchange(PE), Intravenous Immunoglobulin(IVIg)1件: Human immunoglobulin G---1件: 11
154Systemic non-biological treatments----2件: 46, 271
155The Comprehensive Treatment Regimen of Traditional Chinese Medicine----1件: 222
156The Standard Steroid Treatment, Plasma Exchange and rituximab1件: Rituximab1件: D02994 1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 85
157Time delay treatment of botulinum toxin----1件: 149
158TL011, anti CD20, for the treatment of rheumatoid arthritis----1件: 46
159Tocilizumab treatment1件: Tocilizumab1件: D02596 1件: IL6R 💬12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬1件: 41
160Top down treatment if patient at high risk----2件: 96, 97
161Topical Pentoxifylline Gel (Vehicle +PTX)
(Synonym: Trental (TN))
1件: Pentoxifylline (Synonym: Trental Srt 400mg)1件: D00501 (Name: Trental (TN))--1件: 56
162TR004 (Treg immunotherapy)----1件: 96
163Traditional treatment of CGD and TB----1件: 65
164Traditional treatments----1件: 97
165TRE----1件: 86
166Treat to target----1件: 46
167Treat with lansoprazole 30 mg BID for 2 weeks, endoscopic examination with esophageal biopsy for patients with persistent symptoms1件: Lansoprazole (Synonym: Rugby Heartburn Treatment)1件: D00355 2件: ATP4A,
ATP4B 💬
4件: Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation 💬1件: 98
168Treatment----2件: 41, 299
169Treatment A----2件: 34, 46
170Treatment Algorithm A----1件: 97
171Treatment Algorithm B----1件: 97
172Treatment Algorithm C----1件: 97
173Treatment as Usual (TAU)----1件: 85
174Treatment B----2件: 34, 46
175Treatment BX1514M----1件: 58
176Treatment C----2件: 34, 46
177Treatment D----1件: 34
178Treatment defined only by active substance----1件: 50
179Treatment I----1件: 46
180Treatment II----1件: 46
181Treatment III----1件: 46
182Treatment of MTX----1件: 46
183Treatment of MTX and HCQ----1件: 46
184Treatment of MTX and TwHF----1件: 46
185Treatment of TCM----1件: 46
186Treatment of TwHF----1件: 46
187Treatment Phase Group 4----1件: 113
188Treatment systemic therapy (prednisone)1件: Prednisone1件: D00473 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 162
189Treatment taken----1件: 113
190Treatment vs control bread----1件: 97
191Treatment with Adalimumab1件: Adalimumab1件: D02597 1件: TNF 💬67件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬1件: 96
192Treatment with azathioprin----1件: 95
193Treatment with cystic fibrosis transmembrane regulator (CFTR) modualtors Ivacaftor, Lumacaftor-Ivacaftor, Tezacaftor-Ivacaftor, Elexacaftor-Tezacaftor-Ivacaftor4件: Elexacaftor,
Ivacaftor,
Lumacaftor,
Tezacaftor
4件: D09916 ,
D10134 ,
D11041 ,
D11507
1件: CFTR 💬8件: ABC transporters, AMPK signaling pathway, Bile secretion, Gastric acid secretion, Pancreatic secretion, Tight junction, Vibrio cholerae infection, cAMP signaling pathway 💬1件: 299
194Treatment with mycophenolat mofetil----1件: 95
195Treatment with polyethylene glycol (Macrogol 4000)1件: Polyethylene glycol1件: D03370 --1件: 299
196Treatment with systemic therapy (doxycycline)1件: Doxycycline2件: D00307 ,
D07876
--1件: 162
197Treatment with systemic therapy (methotrexate)1件: Methotrexate (Synonym: Trexall)1件: D00142 2件: DHFR,
DHFR2 💬
5件: Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬1件: 162
198Treatment with systemic therapy (prednisone)1件: Prednisone1件: D00473 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 162
199Treatment with topical superpotent corticosteroid therapy----1件: 162
200Tregalizumab1件: Tregalizumab---1件: 46
201Trehalose1件: Trehalose---3件: 2, 6, 113
202TREMFYA1件: Guselkumab (Synonym: Tremfya)1件: D10438 (Name: Tremfya (TN))1件: IL23A 💬9件: C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬2件: 37, 97
203TREMFYA®1件: Guselkumab (Synonym: Tremfya)1件: D10438 (Name: Tremfya (TN))1件: IL23A 💬9件: C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬2件: 37, 97
204TREOSULFAN1件: Treosulfan1件: D07253 (Name: Treosulfan)--6件: 13, 19, 62, 65, 283, 286
205Treprosinil Diethanolamine----1件: 86
206Treprostin----1件: 86
207Treprostinil1件: Treprostinil1件: D06213 (Name: Treprostinil)1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬6件: 51, 84, 85, 86, 88, 210
208Treprostinil dietanolamina1件: Treprostinil1件: D06213 (Name: Treprostinil)1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
209Treprostinil diethanolamine1件: Treprostinil1件: D06213 (Name: Treprostinil)1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬2件: 51, 86
210Treprostinil Diolamine1件: Treprostinil1件: D06213 (Name: Treprostinil)1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
211Treprostinil Inhalation Powder1件: Treprostinil1件: D06213 (Name: Treprostinil)1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
212Treprostinil inhalations1件: Treprostinil1件: D06213 (Name: Treprostinil)1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
213Treprostinil Injectable Product1件: Treprostinil1件: D06213 (Name: Treprostinil)1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
214Treprostinil Palmitil1件: Treprostinil1件: D06213 (Name: Treprostinil)1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
215TREPROSTINIL SODIUM1件: Treprostinil1件: D06213 (Name: Treprostinil)1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬3件: 51, 86, 88
216Treprostinil sodium for inhalation1件: Treprostinil1件: D06213 (Name: Treprostinil)1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 85
217Treprostinil Sodium Solution for Inhalation1件: Treprostinil1件: D06213 (Name: Treprostinil)1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
218TREPROSTINIL SODIUM, UT-151件: Treprostinil1件: D06213 (Name: Treprostinil)1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
219Treprostinil, UT-15, LRX-15, 15AU81, BW A15AU, U-62, 8401件: Treprostinil1件: D06213 (Name: Treprostinil)1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
220Treprostinilo1件: Treprostinil1件: D06213 (Name: Treprostinil)1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
221Tretinoin1件: Tretinoin1件: D00094 (Name: Tretinoin)3件: PML,
RARA,
RARB 💬
12件: Acute myeloid leukemia, Endocytosis, Estrogen signaling pathway, Gastric cancer, Herpes simplex virus 1 infection, Influenza A, Non-small cell lung cancer, Pathways in cancer, Small cell lung cancer, Th17 cell differentiation, Transcriptional misregulation in cancer, Ubiquitin mediated proteolysis 💬3件: 2, 62, 75
222Tretinoin and Pioglitazone HCL2件: Pioglitazone,
Tretinoin
2件: D00094 (Name: Tretinoin),
D08378
4件: PML,
PPARG,
RARA,
RARB 💬
21件: AMPK signaling pathway, Acute myeloid leukemia, Endocytosis, Estrogen signaling pathway, Gastric cancer, Herpes simplex virus 1 infection, Huntington disease, Influenza A, Lipid and atherosclerosis, Longevity regulating pathway, Non-alcoholic fatty liver disease, Non-small cell lung cancer, Osteoclast differentiation, PPAR signaling pathway, Pathways in cancer, Small cell lung cancer, Th17 cell differentiation, Thermogenesis, Thyroid cancer, Transcriptional misregulation in cancer, Ubiquitin mediated proteolysis 💬1件: 2
223TRETINOINA1件: Tretinoin1件: D00094 (Name: Tretinoin)3件: PML,
RARA,
RARB 💬
12件: Acute myeloid leukemia, Endocytosis, Estrogen signaling pathway, Gastric cancer, Herpes simplex virus 1 infection, Influenza A, Non-small cell lung cancer, Pathways in cancer, Small cell lung cancer, Th17 cell differentiation, Transcriptional misregulation in cancer, Ubiquitin mediated proteolysis 💬1件: 75
224Trexan----2件: 46, 97
225Trexan inj 25 mg/ml----1件: 97
226Trexan+Salazopyrin+Oxiklorin+prednisolone1件: Prednisolone1件: D00472 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 46
227Trexan+Salazopyrin+Oxiklorin+prednisolone + infliximab2件: Infliximab,
Prednisolone
2件: D00472 ,
D02598
2件: NR3C1,
TNF 💬
68件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Neuroactive ligand-receptor interaction, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬1件: 46
228TYVASO® (treprostinil) inhalation solution, for oral inhalation use1件: Treprostinil1件: D06213 (Name: Treprostinil)1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 85
229Untreated to atorvastatin treatment1件: Atorvastatin1件: D07474 1件: HMGCR 💬4件: AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis 💬1件: 13
230Usual dopaminergic per os treatment----1件: 6
231UT-15C (treprostinil diethanolamine)1件: Treprostinil1件: D06213 (Name: Treprostinil)1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
232UT-15C SR (treprostinil diethanolamine)1件: Treprostinil1件: D06213 (Name: Treprostinil)1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
233Vancomycin Pre-Treat1件: Vancomycin1件: D00212 --1件: 97
234Vancomycin Pre-Treatment1件: Vancomycin1件: D00212 --1件: 97
235Viral load driven treatment interruption----1件: 265